This article is more than 5 years old. Information may no longer be current.
Cardiology Today's top 5 articles posted in August
Click Here to Manage Email Alerts
Cardiology Today compiled a list of the top 5 stories posted to Healio.com/Cardiology in August.
This month, Cardiology Today’s readers were most interested in statin discontinuation following first ischemic stroke, implications of imaging and FFR-CT, the results of the CANTOS trial, PRECISION-ABPM study results, medical savings programs and much more.
Statin discontinuation post-stroke increases risk for recurrence
Discontinuation of statin therapy within 3 to 6 months following a first ischemic stroke was associated with a 42% higher risk for recurrent stroke within 1 year, researchers reported in the Journal of the American Heart Association.
CTA, FFR-CT changing management of suspected angina, CAD
Testing strategies are rapidly evolving to determine which patients with chest pain have CAD, and which of those have high enough risk to warrant revascularization. Driving reexamination of historical approaches to evaluate such patients are advances in coronary CT angiography technology, including new capabilities to determine coronary fractional flow reserve from CT images (FFR-CT).
CANTOS: Canakinumab reduces recurrent CV event rates in MI, inflammation
Patients with a history of MI and an elevated high-sensitivity C-reactive protein level treated with canakinumab had a lower rate of recurrent CV events compared with placebo, according to results of the CANTOS trial presented at the European Society of Cardiology Congress.
PRECISION-ABPM: Ibuprofen increases systolic BP, hypertension risk in arthritis
Patients with osteoarthritis or rheumatoid arthritis and elevated risk for CVD who were treated with ibuprofen had increased systolic BP in addition to the risk for hypertension vs. those treated with celecoxib, according to the PRECISION-ABPM study.
Medicare savings program fails to improve medication use, adherence
Exposure to the Medicare Shared Savings Program was not associated with increased medication use or adherence among patients with CVD and diabetes, according to recent findings.